Since topotecan is one of the most effective drugs for the treatment of cervical cancer and because its combination with cisplatin is effective as second-line chemotherapy in patients with advanced/recurrent cervical cancer 58, the current study examined the role of DAPK1 in the response to topotecan. This evidence concerns the gene DAPK1 and cervical carcinoma.